$LLY

$LLY · Schwab Network · 2026-11-13

AI 摘要 · Schwab Network

Eli Lilly 是一个高溢价成长故事:在表现出色的一年里上涨35%,也是医疗保健板块上涨行情的领跑者之一;它凭借三款领先的 GLP1 产品抓住了医疗保健领域最大的机会,有利的人口结构持续为强劲的研发管线提供顺风,因此其高溢价估值是合理的。

看涨
《PPI Mostly Cool, AI at "Crossroads" Amid NVDA CEO Search》
Schwab Network发布 2026-11-13 · 2 段内容

播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策

03:05/ —打开原视频

逐段跳播

2 段内容

Eli Lilly 是你名单上的名字之一。我猜这是对 GLP1 领域的押注,但请给我们讲讲你的投资逻辑。正是如此。Eli Lilly 今年表现很好,上涨了35%,确实是这轮医疗保健行情中的领跑者之一。

正如你提到的,他们凭借三款领先的 GLP1 产品,抓住了当前医疗保健领域最大的机会。

Eli Lilly is one of those names on your list. I'm betting this is a bet on the GLP1 space, but walk us through your thesis here. Exactly. You know, Eli Lilly's had a great year up 35% and really one of the leaders of that healthcare run.

As you mentioned, they've been able to capitalize on, you know, really the the biggest opportunity right now in healthcare with their three leading GLP1 products.

除此之外,我认为他们拥有人口结构方面的有利因素,这继续为其强大的研发管线提供顺风。我认为值得注意的是,你为这只股票支付了溢价,但我确实相信这是一个溢价成长的故事。

Um you know, beyond that, I think they have favorable demographics that continue to be tailwinds to their strong pipeline. Um you know, I I think it's worth noting, you know, you're paying a premium for this stock, but I do believe it's a a premium growth story.

这个频道对 $LLY 的历次判断

Schwab Network 在这只股票上共 7 条判断,这里只列相邻的几条。

跨洋听风